ALLO - Allogene Therapeutics Inc logo

ALLO

Allogene Therapeutics Inc

Allogene Therapeutics develops genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. Its pipeline includes CAR T cell candidates targeting CD19 and CD70 for conditions like large B-cell lymphoma and renal cell carcinoma.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$98today

Score Overview

1 Year
Scoreโ€”
Net Growth8.97%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.4
Net Growth29.03%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth17.85%
Net Trend63%
Net Income Consistency
Rev Growthโ€”
Rev Trend25%
Revenue Consistency

See the full market ranking โ†’

Allogene Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 38M to $ 0.00 and net income went from -$ 233M to -$ 190M. Revenue increased in 0 of those 5 years; net income in 4.

Allogene Therapeutics Inc currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.07โ€”
1 Year2025-08-12
$ 1.03100.97%
5 Years2021-08-12
$ 21.17-90.22%
All Time2018-10-11
$ 25.00-91.72%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 173M$ 266M
2025$ 0.00-$ 190M$ 250M
2024$ 22K-$ 257M$ 292M
2023$ 95K-$ 327M$ 448M
2022$ 243K-$ 329M$ 517M
2021$ 38M-$ 244M$ 457M
2020$ 38M-$ 233M$ 827M
2019$ 0.00-$ 184M$ 530M
IPO2018$ 0.00-$ 211M$ 721M

Explore beyond ALLO

You're looking at Allogene Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies